- 點擊【立即啟動】(藍框處)打開 Microsoft Edge
Oneness announces the information about the investor's conference of 2022 Q2.
The findings of the MoA studies on Fespixon(ON101) under collaboration with TMU and NYCU have been accepted and published by a renown SCI journal, JID Innovations
Oneness Biotech Co.,LTD receives a China patent on antagonistic PDL1 aptamers.
The Annual General Shareholders' Meeting approved the removal of non-competition restriction on the newly-elected director.
By-election of one director of the board in 2022 shareholders' meeting
Oneness announce the important resolutions of the 2022 Annual General Shareholders' Meeting
The Company's 2022Q1 consolidated financial statements have been approved by the Board of Directors
Oneness received the notification by the international CRO on the unblinded data of FB825 Phase 2a study in moderate-to-severe atopic dermatitis in the U.S.
News-Oneness Ranked among Top 5% in the 8th Corporate Governance Evaluation
The Food and Drug Administration–Philippines (PFDA) has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon
Oneness Biotech has been invited to present at the "11th Taiwan CEO Week" online investor's conference co-organized by TWSE and QIC
Oneness Biotech Co., Ltd. receives ISO13485 Medical Devices Quality Management System Certificate.
Oneness re-announces the Board of Directors resolved to convene the Annual Shareholders' Meeting of 2022.(Method of convening the meeting: hybrid shareholders' meeting)
Oneness announces the information about the investor's conference of 2022 Q1.
Oneness Biotech Co., Ltd. receives an Indonesian patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).